The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A humanized antibody that binds to the interleukin 2 receptor.
Open accessAbstract
The anti-Tac monoclonal antibody is known to bind to the p55 chain of the human interleukin 2 receptor and to inhibit proliferation of T cells by blocking interleukin 2 binding. However, use of anti-Tac as an immunosuppressant drug would be impaired by the human immune response against this murine antibody. We have therefore constructed a "humanized" antibody by combining the complementarity-determining regions (CDRs) of the anti-Tac antibody with human framework and constant regions. The human framework regions were chosen to maximize homology with the anti-Tac antibody sequence. In addition, a computer model of murine anti-Tac was used to identify several amino acids which, while outside the CDRs, are likely to interact with the CDRs or antigen. These mouse amino acids were also retained in the humanized antibody. The humanized anti-Tac antibody has an affinity for p55 of 3 x 10(9) M-1, about 1/3 that of murine anti-Tac.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Yanisch-Perron, C., Vieira, J., & Messing, J. (1985) · Gene · doi:10.1016/0378-1119(85)90120-9 · Cited by 15,041
A simple and very efficient method for generating cDNA libraries
Gubler, U., & Hoffman, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90230-5 · Cited by 4,510
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Uchiyama, T., Broder, S., & Waldmann, T. A. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.4.1393 · Cited by 1,329
Self-citationChimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Leonard, W. J., Depper, J. M., Uchiyama, T., Smith, K. A., Waldmann, T. A., & Greene, W. C. (1982) · Nature · doi:10.1038/300267a0 · Cited by 864
Self-citationREMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M. R., Marcus, R., Winter, G., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
Cited by
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Anatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes
Urano, Y., Asanuma, D., Hama, Y., Koyama, Y., Barrett, T., Kamiya, M., Nagano, T., Watanabe, T., Hasegawa, A., Choyke, P. L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1854 · Cited by 801
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Self-citationBielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H., Henkart, P. A., & Martin, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601335103 · Cited by 597
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 559
The structural basis of antibody–antigen recognition
Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530
Antibody framework residues affecting the conformation of the hypervariable loops
Foote, J., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)91010-m · Cited by 524
Kahan, B. D., Rajagopalan, P. R., & Hall, M. (1999) · Transplantation · doi:10.1097/00007890-199901270-00016 · Cited by 476
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137345 · Cited by 475
Suthanthiran, M., & Strom, T. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310606 · Cited by 469
Murphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
Yin, H., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461786 · Cited by 453
By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling
Marks, J. D., Griffiths, A. D., Malmqvist, M., Clackson, T. P., Bye, J. M., & Winter, G. (1992) · Nature Biotechnology · doi:10.1038/nbt0792-779 · Cited by 404
A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer Cells
Freud, A. G., Becknell, B., Roychowdhury, S., Mao, H. C., Ferketich, A. K., Nuovo, G. J., Hughes, T. L., Marburger, T. B., Sung, J., Baiocchi, R. A., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.013 · Cited by 401
Monoclonal Antibodies in Diagnosis and Therapy
Waldmann, T. A. (1991) · Science · doi:10.1126/science.2047874 · Cited by 385
Self-citationWaldmann, T. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49895-x · Cited by 345
Self-citationContribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies
Ionescu, R. M., Vlasak, J., Price, C., & Kirchmeier, M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21104 · Cited by 313
Handbook of Affinity Chromatography
(2005) · CRC Press eBooks · doi:10.1201/9780824751982 · Cited by 310
REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1
Nashan, B., Light, S., Hardie, I. R., Lin, A., & Johnson, J. R. (1999) · Transplantation · doi:10.1097/00007890-199901150-00019 · Cited by 302
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I., Lu, J.-G., Gajewski, J., Durett, A., Cleary, K., et al. (2000) · Blood · doi:10.1182/blood.v95.1.83 · Cited by 263
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1484 · Cited by 258
Advances in interleukin 2 receptor targeted treatment
Morris, J. C., & Waldmann, T. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i109 · Cited by 131
“25 Humanised anti-Tac (HAT) has the advantages of a low incidence of induction of neutralising antibodies, a signifi-cantly prolonged serum half life (t 1/2 ) of 20 days compared with 40 hours for the murine antibody, and the ability to mediate antibody dependent cytotoxicity (ADCC) through its…”
BackgroundSelf-citationAnalyzing the ‘Degree of Humanness’ of antibody sequences
Abhinandan, K. R., & Martin, A. C. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.100 · Cited by 99
“Antibody Source of sequence Zenapax Queen et al (1989).”
BackgroundGoralczyk, A. D., Hauke, N., Bari, N., Y. Tsui, T., Lorf, T., & Obed, A. (2011) · Hepatology · doi:10.1002/hep.24385 · Cited by 72
Bench to bedside: new approaches to the immunotherapy of uveitic disease
NUSSENBLATT, R. B. (2002) · International Reviews of Immunology · doi:10.1080/08830180212067 · Cited by 72
Chen, J., Zhang, M., Ju, W., & Waldmann, T. A. (2009) · Blood · doi:10.1182/blood-2008-04-149658 · Cited by 49
Self-citationEvolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44
Goydel, R. S., Weber, J., Peng, H., Qi, J., Soden, J., Freeth, J., Park, H., & Rader, C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012791 · Cited by 34
Metadata
- Authors
- Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1989-12
- Volume
- 86
- Issue
- 24
- Pages
- 10029-10033
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2052150715
- Cited by
- 627
- References
- 28
- FWCI
- 24.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.